Research
Hormonal
n-6 fatty acids, specifically arachidonic acid (AA), increase the susceptibility of cardiomyocytes to apoptosis and arrhythmias during ischemia/reperfusion injury through Ca2+/Na+ mediated actions and increased inflammatory biomarkers.
Maintain a healthy balance between n-6 and n-3 fatty acids. While n-6 fats are essential, excessive intake relative to n-3 fats may increase inflammation and heart cell damage during stress. Focus on reducing processed foods high in n-6 oils and increasing n-3 sources.
ModerateRefutesMEDIUM confidence
Administration of 40 (cid:2)M arachidonic acid (AA) upregulated apoptotic pathways within the myocyte. AA increased the levels of intracellular calcium and sodium and this was correlated with increased caspase-3 activity and cytochrome c release. The data suggests that AA increases the susceptibility of the myocyte to undergo apoptosis through a Ca2+/Na+ mediated action.
Why this rating
Evidence is primarily from in vitro and animal models; human clinical data is less direct for this specific mechanism.
Source
Trans Fatty Acids and Cardiovascular Disease
Dariush Mozaffarian et al. · New England Journal of Medicine · 2006
DOI 10.1056/nejmra054035
narrative_reviewCited 1,756×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Consumption of industrial trans fatty acids (iTFA) increases the risk of cardiovascular disease and myocardial infarction through pro-inflammatory actions and atherosclerosis development, whereas ruminant trans fatty acids (rTFA) may possess anti-atherogenic properties.Good
- Consumption of n-3 polyunsaturated fatty acids (PUFAs), specifically EPA and DHA, provides cardioprotection by reducing inflammation, preventing microthrombus formation, and improving survival post-ischemia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →